Baseline Characteristics and Treatment Response to Ixekizumab Categorised by Sex in Radiographic and Non-radiographic Axial Spondylarthritis Through 52 Weeks: Data from Three Phase III Randomised Controlled Trials

Irene E van der Horst-Bruinsma, Kurt de Vlam, Jessica A Walsh, Rebecca Bolce, Theresa Hunter, David Sandoval, Danting Zhu, Vladimir Geneus, Enrique R Soriano, Marina Magrey, Irene E van der Horst-Bruinsma, Kurt de Vlam, Jessica A Walsh, Rebecca Bolce, Theresa Hunter, David Sandoval, Danting Zhu, Vladimir Geneus, Enrique R Soriano, Marina Magrey

Abstract

Objectives: Assess baseline characteristics and treatment response to ixekizumab (IXE) categorised by sex in patients with radiographic axial spondyloarthritis (r-axSpA) and non-radiographic axSpA (nr-axSpA) up to 52 weeks.

Methods: Data were analysed from three randomised controlled trials of IXE through 52 weeks. Patients fulfilled ASAS classification criteria for r-axSpA or nr-axSpA and were randomised to receive 80 mg subcutaneous administration of IXE every 2 weeks (Q2W) or 4 weeks (Q4W), or placebo (16 weeks COAST-V/W; 52 weeks COAST-X). Baseline characteristics and treatment outcomes were assessed. Patients were categorised by sex; methods included non-responder imputation for categorical variables, and modified baseline observation carried forward for continuous efficacy variables.

Results: At presentation, female patients had higher disease burden as reflected by significantly higher spinal pain at night, fatigue scores and pain/swelling in joints other than the neck, back or hip. ASAS40 response rate with the approved label dose, IXEQ4W, was achieved in 39% of male patients with r-axSpA by week 16, and 44% by week 52. For female patients, 16.7% and 33.3% achieved ASAS40 at week 16 and 52, respectively. In nr-axSpA, 46% of male patients achieved ASAS40 at week 16 and 30% at week 52. In total, 23.9% of female patients achieved ASAS40 at week 16, and 30.4% at week 52.

Conclusions: This analysis demonstrates that for the axSpA disease spectrum, female patients present with higher disease burden. Following treatment with IXE, there is a higher proportion of male responders up to 16 weeks, while female patients show less robust responses for the first 16 weeks but larger responses from weeks 16 through 52.

Trial registration numbers: NCT02696785, NCT02696798 and NCT02757352.

Keywords: Axial spondyloarthritis; Ixekizumab; Non-radiographic; Radiographic; Sex differences.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
COAST-V/W and COAST-X ASAS40 (ITT, NRI). Patients initially randomised to PBO in COAST-V/W switched to IXEQ2W or Q4W at week 16 by study design; PBO data are summarised up to week 16. Data displayed as mean. Significantly greater response rate versus PBO following IXE treatment denoted by * (p ≤ 0.05), ** (p ≤ 0.01), *** (p ≤ 0.001). ASAS40 Assessment in SpondyloArthritis International Society 40%, Q4W every 4 weeks, Q2W every 2 weeks, ITT intent-to-treat population, NRI non-responder imputation, PBO placebo, IXE ixekizumab
Fig. 2
Fig. 2
ASDAS LDA p ≤ 0.05), ** (p ≤ 0.01), *** (p ≤ 0.001). ASDAS Ankylosing Spondylitis Disease Activity Score, LDA low disease activity, Q4W every 4 weeks, Q2W every 2 weeks, ITT intent-to-treat population, NRI non-responder imputation, PBO placebo, IXE ixekizumab

References

    1. Akkoc N, Khan MA. Is axial spondyloarthritis more common than rheumatoid arthritis? Curr Rheumatol Rep. 2020;22(9):54. doi: 10.1007/s11926-020-00934-3.
    1. Reveille JD, Witter JP, Weisman MH. Prevalence of axial spondylarthritis in the United States: estimates from a cross-sectional survey. Arthritis Care Res (Hoboken) 2012;64(6):905–910. doi: 10.1002/acr.21621.
    1. Rusman T, van Vollenhoven RF, van der Horst-Bruinsma IE. Gender differences in axial spondyloarthritis: women are not so lucky. Curr Rheumatol Rep. 2018;20(6):35. doi: 10.1007/s11926-018-0744-2.
    1. West HF. Aetiology of ankylosing spondylitis. Ann Rheum Dis. 1949;8:143–148. doi: 10.1136/ard.8.2.143.
    1. Kennedy LG, Will R, Calin A. Sex ratio in the spondyloarthropathies and its relationship to phenotypic expression, mode of inheritance and age at onset. J Rheumatol. 1993;20(11):1900–1904.
    1. Neuenschwander R, Hebeisen M, Micheroli R, et al. Differences between men and women with nonradiographic axial spondyloarthritis: clinical characteristics and treatment effectiveness in a real-life prospective cohort. Arthritis Res Ther. 2020;22(1):233. doi: 10.1186/s13075-020-02337-2.
    1. Lee W, Reveille JD, Weisman MH. Women with ankylosing spondylitis: a review. Arthritis Rheum. 2008;59(3):449–454. doi: 10.1002/art.23321.
    1. Tournadre A, Pereira B, Lhoste A, et al. Differences between women and men with recent-onset axial spondyloarthritis: results from a prospective multicenter French cohort. Arthritis Care Res (Hoboken) 2013;65(9):1482–1489. doi: 10.1002/acr.22001.
    1. de Carvalho HM, Bortoluzzo AB, Gonçalves CR, et al. Gender characterization in a large series of Brazilian patients with spondyloarthritis. Clin Rheumatol. 2012;31(4):687–695. doi: 10.1007/s10067-011-1890-3.
    1. Jovaní V, Blasco-Blasco M, Ruiz-Cantero MT, Pascual E. Understanding how the diagnostic delay of spondyloarthritis differs between women and men: a systematic review and metaanalysis. J Rheumatol. 2017;44(2):174–183. doi: 10.3899/jrheum.160825.
    1. Horst-Bruinsma IVD, Hunter T, Bolce R, Holdsworth E, Booth N. SAT0332 gender differences in disease status, quality of life and treatment patterns among axial spondyloarthritis patients: findings from a global survey. Ann Rheum Dis. 2019;78(Suppl 2):1245–1245.
    1. Webers C, Essers I, Ramiro S, et al. Gender-attributable differences in outcome of ankylosing spondylitis: long-term results from the Outcome in Ankylosing Spondylitis International Study. Rheumatology (Oxford) 2016;55(3):419–428.
    1. Swinnen TW, Westhovens R, Dankaerts W, de Vlam K. Widespread pain in axial spondyloarthritis: clinical importance and gender differences. Arthritis Res Ther. 2018;20(1):156. doi: 10.1186/s13075-018-1626-8.
    1. Ibn Yacoub Y, Amine B, Laatiris A, Hajjaj-Hassouni N. Gender and disease features in Moroccan patients with ankylosing spondylitis. Clin Rheumatol. 2012;31(2):293–297. doi: 10.1007/s10067-011-1819-x.
    1. Walsh J, Hunter T, Schroeder K, Sandoval D, Bolce R. Trends in diagnostic prevalence and treatment patterns of male and female ankylosing spondylitis patients in the United States, 2006–2016. BMC Rheumatol. 2019;3:39. doi: 10.1186/s41927-019-0086-3.
    1. Barnabe C, Bessette L, Flanagan C, et al. Sex differences in pain scores and localization in inflammatory arthritis: a systematic review and metaanalysis. J Rheumatol. 2012;39(6):1221–1230. doi: 10.3899/jrheum.111393.
    1. San Koo B, Kim TH. The role of ixekizumab in non-radiographic axial spondyloarthritis. Ther Adv Musculoskelet Dis. 2021;13:1759720x20986734. doi: 10.1177/1759720X20986734.
    1. McGonagle DG, McInnes IB, Kirkham BW, Sherlock J, Moots R. The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies. Ann Rheum Dis. 2019;78(9):1167–1178. doi: 10.1136/annrheumdis-2019-215356.
    1. Gracey E, Yao Y, Green B, et al. Sexual dimorphism in the Th17 signature of ankylosing spondylitis. Arthritis Rheumatol. 2016;68(3):679–689. doi: 10.1002/art.39464.
    1. van der Heijde D, Cheng-Chung Wei J, Dougados M, et al. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. Lancet. 2018;392(10163):2441–2451. doi: 10.1016/S0140-6736(18)31946-9.
    1. Deodhar A, van der Heijde D, Gensler LS, et al. Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial. Lancet. 2020;395(10217):53–64. doi: 10.1016/S0140-6736(19)32971-X.
    1. Deodhar A, Poddubnyy D, Pacheco-Tena C, et al. Efficacy and safety of ixekizumab in the treatment of radiographic axial spondyloarthritis: sixteen-week results from a phase III randomized, double-blind, placebo-controlled trial in patients with prior inadequate response to or intolerance of tumor necrosis factor inhibitors. Arthritis Rheumatol. 2019;71(4):599–611. doi: 10.1002/art.40753.
    1. Rusman T, van Bentum RE, van der Horst-Bruinsma IE. Sex and gender differences in axial spondyloarthritis: myths and truths. Rheumatology (Oxford) 2020;59(Suppl4):iv38–iv46. doi: 10.1093/rheumatology/keaa543.
    1. Wright GC, Kaine J, Deodhar A. Understanding differences between men and women with axial spondyloarthritis. Semin Arthritis Rheum. 2020;50(4):687–694. doi: 10.1016/j.semarthrit.2020.05.005.
    1. van der Horst-Bruinsma IE, Zack DJ, Szumski A, Koenig AS. Female patients with ankylosing spondylitis: analysis of the impact of gender across treatment studies. Ann Rheum Dis. 2013;72(7):1221–1224. doi: 10.1136/annrheumdis-2012-202431.
    1. Fillingim RB, King CD, Ribeiro-Dasilva MC, Rahim-Williams B, Riley JL., 3rd Sex, gender, and pain: a review of recent clinical and experimental findings. J Pain. 2009;10(5):447–485. doi: 10.1016/j.jpain.2008.12.001.
    1. Mogil JS, Bailey AL. Sex and gender differences in pain and analgesia. Prog Brain Res. 2010;186:141–157.
    1. Mogil JS. Sex differences in pain and pain inhibition: multiple explanations of a controversial phenomenon. Nat Rev Neurosci. 2012;13(12):859–866. doi: 10.1038/nrn3360.
    1. Leresche L. Defining gender disparities in pain management. Clin Orthop Relat Res. 2011;469(7):1871–1877. doi: 10.1007/s11999-010-1759-9.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner